肿瘤患者CYP2C8基因多态性与紫杉醇不良反应的相关性研究

许秋霞, 周细萍, 叶磊, 庄奕筠, 陈金成, 张吟

中国药学杂志 ›› 2019, Vol. 54 ›› Issue (12) : 1007-1011.

PDF(1094 KB)
中国药学杂志
PDF(1094 KB)
中国药学杂志 ›› 2019, Vol. 54 ›› Issue (12) : 1007-1011. DOI: 10.11669/cpj.2019.12.014
论著

肿瘤患者CYP2C8基因多态性与紫杉醇不良反应的相关性研究

  • 许秋霞1a, 周细萍2, 叶磊1b, 庄奕筠1a, 陈金成1a, 张吟1a
作者信息 +

Correlation Study between CYP2C8 Gene Polymorphim and Adverse Reaction of Paclitaxel in Cancer Patients

  • XU Qiu-xia1a, ZHOU Xi-ping2, YE Lei1b, ZHUANG Yi-jun1a, CHEN Jin-cheng1a, ZHANG Yin1a
Author information +
文章历史 +

摘要

目的 探讨肿瘤患者CYP2C8基因多态性与紫杉醇不良反应的关系。方法 选择我院2016年1月~2018年5月接受紫杉醇化疗的肿瘤患者52例作为研究对象,检测其CYP2C8基因型,并观察、收集、记录其不良反应发生情况,分析患者的不良反应发生和基因多态性的相关性。结果 本研究共检测了25个基因位点,仅7个基因位点有发生突变,其余18个基因位点均为野生型。本研究发现,在CYP2C8基因多态性中,携带CYP2C8*1B(-271 C>A)野生型基因(CC)患者的血小板减少和疼痛的发生率均高于突变型基因(CA+AA),差异有统计学意义(P＜0.05);携带CYP2C8*2/*3(32299 C>T)野生型基因(CC)患者的肝脏毒性发生率低于突变型基因(CT+TT),差异有统计学意义(P＜0.05)。结论 CYP2C8基因多态性与紫杉醇的不良反应可能具有相关性。

Abstract

OBJECTIVE To investigate the correlation between CYP2C8 gene polymorphisms and the adverse reactions of paclitaxelin in cancer patients. METHODS Fifty-two patients who received paclitaxel chemotherapy from January 2016 to May 2018 were selected as experimental subjects. The CYP2C8 genotypes of the selected patients were tested and the adverse reactions of paclitaxel were observed, collected and recorded to explore the relationship between adverse reactions and genetic polymorphism. RESULTS In this study, 25 gene loci were detected, only 7 gene loci had mutation, and the remaining 18 gene loci were all wild-type.In the polymorphism of CYP2C8 gene,the incidence of thrombocytopenia and pain in patients with CYP2C8*1B(-271C>A) wild-type (CC) was significantly higher than that in mutant (CA+AA) (P<0.05). And the incidence of hepatotoxicity in patients with CYP2C8*2/*3(32299C>T) wild-type gene (CC) was significantly lower than that in mutant gene (CT+TT) (P<0.05). CONCLUSION The polymorphism of CYP2C8 gene may be associated with the adverse reaction of paclitaxel.

关键词

紫杉醇 / 基因多态性 / CYP2C8 / 不良反应

Key words

paclitaxel / geneticpolymorphism / CYP2C8 / adversereaction

引用本文

EndNote

Ris (Procite)

Bibtex

导出引用
许秋霞, 周细萍, 叶磊, 庄奕筠, 陈金成, 张吟. 肿瘤患者CYP2C8基因多态性与紫杉醇不良反应的相关性研究[J]. 中国药学杂志, 2019, 54(12): 1007-1011 https://doi.org/10.11669/cpj.2019.12.014
XU Qiu-xia, ZHOU Xi-ping, YE Lei, ZHUANG Yi-jun, CHEN Jin-cheng, ZHANG Yin. Correlation Study between CYP2C8 Gene Polymorphim and Adverse Reaction of Paclitaxel in Cancer Patients[J]. Chinese Pharmaceutical Journal, 2019, 54(12): 1007-1011 https://doi.org/10.11669/cpj.2019.12.014
中图分类号： R969.1   

参考文献

[1] NABHOLTZ, JCAN-MARC, GLIGOROV, et al. The role of taxanes in the treatment of breast [J]. Exp Opin Pharm, 2005, 6(7):1073-1094.
[2] PEI B X, SUN Y S, DONG S H. Curative effects of abraxane in patients with non-small-cell lung cancer and breast cancer[J]. Chin Pharm J(中国药学杂志), 2011, 46(23):1851-1854.
[3] JI F R, SONG Y Q, LEI L L, et al. Relationship between CYP3A4*1G gene polymorphism and paclitaxel adverse reactions[J]. Heilongjiang Med Pharm(黑龙江医药科学), 2016, 39(2):7-8.
[4] WANG J, TANG J H, ZHAO J. Genotype polymorphisms of taxane-related metabolizing enzymes and drug-transporterswith chemotherapy reaction for breast cancer[J]. J Mol Diagn Ther(分子诊断与治疗杂), 2010, 2(1):63-67.
[5] RAHMAN A, KORZEKWA K R, GROGAN J, et al. Selective biotransformation of taxol to 6 alpha-hydroxytaxol by human cytochrome P450 2C8[J]. Cancer Res, 1994, 54:5543-5546.
[6] CAI W M. The application prospect of pharmacogenomics in the individualized administration of antitumor drugs[J]. Chin Hosp Pharm J(中国医院药学杂), 2009, 29(16):1393-1396.
[7] SOYAMA A, SAITO Y, HANIOKA N, et al. Non-synonymous singlenucleotide alterations found in the CYP2C8 gene result in reduced in vitro paclitaxel metabolism[J]. Biol Pharm Bull, 2001, 24:1427-1430.
[8] BERGMANN T K, BRASCH-ANDERSEN C, GR EN H, et al. Impact of CYP2C8*3 on paclitaxel clearance:a population pharmacokinetic and pharmacogenomic study in 93 patients with ovarian cancer [J]. Pharmacogenomics J, 2011, 11:113 -120.
[9] LESKEL S, JARA C, LEANDRO-GARC A L J, et al. Polymorphisms in cytochromes P450 2C8 and 3A5 are associated with paclitaxel neurotoxicity[J]. Pharmacogenomics J, 2011, 11(2):121-129.
[10] WU H P. Clinical application and adverse reactions of taxol[J]. Strait Pharm J(海峡药学), 2009, 21(6):234-236.
[11] YU J W, LU Z H, GAO J, et al. Research progress in chemoresistance mechanism of paclitaxel and the future direction[J]. Chin Pharm J(中国药学杂志), 2013, 48(14):1147-1150.
[12] DENG J H, XIAO L, SHI D H. Advances in pharmacogenomics of paclitaxel for ovarian cance[J]. J China Pharm(中国药房), 2012,23(40):3831-3833.
[13] DAI D, ZELDIN D C, BLAISDELL J A, et al. Polymorphisms in human CYP2C8 decrease metabolism of the anticancer drug paclitaxel and arachidonic acid[J]. Pharmacogenetics, 2001, 11(7):597-607.
[14] GR EN H, S DERKVIST P, ROSENBERG P, et al. Pharmacogenetic studies of paclitaxel in the treatment of ovarian cancer[J]. Basic Clin Pharmacol Toxicol, 2009, 104(2):130-137.
[15] MARSH S, PAUL J, KING C R, et al. Pharmacogenetic assessment of yoxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer:the scottish randomisedtrial in ovarian cancer[J]. J Clin Oncol, 2007, 25(29):4528-4535.
[16] SISSUNG T M, MROSS K, STEINBERG S M, et al. Associationof ABCB1 genotypes with paclitaxel-mediated peripheral neuropathy and neutropenia[J]. Eur J Cancer, 2006, 42(17):2893-2896.

基金

福建省科技厅社会发展引导性(重点)项目资助(2015Y0055);福建省卫计委青年科研课题项目资助(2015-1-60);泉州市医疗卫生指导性项目资助(2015QZZD13);福建医科大学附属第二医院苗圃基金项目资助(2013MP05)

PDF(1094 KB)

Accesses

Citation

Detail
段落导航
相关文章

/

〈 〉